Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives - 20/04/22
Abstract |
To date, immune checkpoint blockade (ICB) immunotherapy has become one of promise strategies in the management of patients with unresectable or metastatic colorectal cancer (CRC). However, clinical observations showed that not all the patients responded equally to ICBs, certain group of CRC patients with microsatellite-instability-low (MSI-L) phenotype was not sensitive to ICB immunotherapy. In addition, some primary responders might lose their sensitivity and become resistant to ICBs overtime. To obtain a better response rate and therapeutic efficacy, considerable attempts have been made toward to a precision medicine algorithm. Studies showed that multiple strategies based on the patient’s individual condition might improve the response and therapeutic efficacy to ICBs. Therefore, we focused on and discussed precision strategies and perspectives e.g., how to early define candidates who will benefit from ICB immunotherapy prior treatment, overcome the primary and acquired resistance and improve the therapeutic response to ICBs in CRC patients with different microsatellite-instability statuses within the context of precision medicine algorithm in this review.
Le texte complet de cet article est disponible en PDF.Abbreviations : CAMK1D, CD8 T cell-H, CRC, ctDNA, CTL, CTLA4, dMMR, DNMTi, FMT, ICB, IDO, IFN-γ, IFN-γ-H, ICB, IHC, IL, Immunosuppressive cell-H, IRC, IRF2, LAG3, mAb, MDSCs, MSI-H, MSI-L, MSS, NGS, ORR, OS, PD-1, PD-L1, PD1/PD-L1-H, PD1/PD-L1-L, PFS, pMMR, smMIPs, TILs, TGF-β, TGGA, TIL, TMB, TMB-H, TMB-L, Treg
Keywords : Immune checkpoint, Blockade, Precise medicine, colorectal cancer
Plan
Vol 149
Article 112923- mai 2022 Retour au numéro
Article précédent
- Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC
- Xinlin Liang, Anqi Lin, Qiongyao Wang, Jian Zhang, Peng Luo
- Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
- Sandra Cetin, Damijan Knez, Stanislav Gobec, Janko Kos, Anja Pišlar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?